Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 7/20 | 0.42 |
| ▸ | RARB | P10826 | 7/20 | 0.42 |
| ▸ | RARG | P13631 | 7/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | ATF4 | P18848 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408986 | 0.86 | BDKRB1 (0.40) | RARARARBRARGNR1H4ATF4 | |
| SCHEMBL29408927 | 0.80 | HSD11B1 (0.38) | RARARARBRARGNR1H4HSD11B1 | |
| SCHEMBL22613838 | 0.80 | HSD11B1 (0.38) | RARARARBRARGNR1H4HSD11B1 | |
| SCHEMBL22614128 | 0.79 | KMO (0.44) | RARARARBRARGKMOATF4 | |
| SCHEMBL22613960 | 0.79 | KMO (0.41) | RARARARBRARGKMOTRPV1 | |
| SCHEMBL20734450 | 0.78 | ATF4 (0.62) | ATF4 | |
| SCHEMBL22613923 | 0.77 | ATF4 (0.40) | RARARARBRARGNR1H4ATF4 | |
| SCHEMBL22614614 | 0.77 | ATF4 (0.40) | RARARARBRARGNR1H4ATF4 | |
| SCHEMBL22614152 | 0.77 | ATF4 (0.40) | RARARARBRARGNR1H4ATF4 | |
| SCHEMBL29408953 | 0.77 | ATF4 (0.40) | RARARARBRARGNR1H4ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094244-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3962906-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223538-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | RARA 1922/4885RARB 1343/4885RARG 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.